078650 — G9Pharma Co Income Statement
0.000.00%
- KR₩135m
- KR₩23bn
- KR₩679m
Annual income statement for G9Pharma Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 77,859 | 67,740 | 41,551 | 23,829 | 679 |
Cost of Revenue | |||||
Gross Profit | 13,166 | 11,143 | -23,180 | -14,090 | -723 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 72,801 | 64,722 | 85,199 | 52,219 | 12,324 |
Operating Profit | 5,058 | 3,018 | -43,648 | -28,390 | -11,645 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 6,304 | -8,547 | -45,530 | -37,254 | -38,615 |
Provision for Income Taxes | |||||
Net Income After Taxes | 6,275 | -8,678 | -45,532 | -37,257 | -38,619 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 6,275 | -8,678 | -45,055 | -37,257 | -38,619 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 7,247 | -8,678 | -45,055 | -37,257 | -38,619 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2,576 | -3,380 | -15,540 | -8,907 | -6,353 |
Dividends per Share |